

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 February 2025 (13.02.2025)



(10) International Publication Number
WO 2025/034858 A1

(51) International Patent Classification:

C07D 495/04 (2006.01) A61P 9/00 (2006.01)
C07D 493/04 (2006.01) A61P 35/00 (2006.01)
C07D 403/04 (2006.01) A61K 31/4365 (2006.01)
A61P 3/00 (2006.01) A61K 31/4355 (2006.01)

(21) International Application Number:

PCT/US2024/041288

(22) International Filing Date:

07 August 2024 (07.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/518,242 08 August 2023 (08.08.2023) US
63/666,479 01 July 2024 (01.07.2024) US

(71) Applicants: **THERAS, INC.**, [US/US]; 1 Corporate Drive, South San Francisco, California 94080 (US). **LEIDOS BIOMEDICAL RESEARCH, INC.**, [US/US]; P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **LAWRENCE LIVERMORE NATIONAL SECURITY, LLC** [US/US]; 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US).

(72) Inventors: **XU, Rui**; c/o TheRas, Inc., 1 Corporate Drive, South San Francisco, California 94080 (US). **WANG, Bin**; c/o TheRas, Inc., 1 Corporate Drive, South San Francisco, California 94080 (US). **WALLACE, Eli**; c/o TheRas, Inc., 1 Corporate Drive, South San Francisco, California 94080 (US). **WEHN, Paul**; c/o TheRas, Inc., 1 Corporate Drive, South San Francisco, California 94080 (US). **SIMANSHU, Dhirendra Kumar**; c/o Leidos Biomedical Research, Inc., P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **TURNER, David Michael**; c/o Leidos Biomedical Research, Inc., P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **CZYZYK, Daniel J.**; c/o Leidos Biomedical Research, Inc., P.O. Box B, 1050



Boyles Street, Frederick, Maryland 21701 (US). **SINGH, Swapnil**; c/o Leidos Biomedical Research, Inc., P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **YERABOLU, Jayasudhan Reddy**; c/o Leidos Biomedical Research, Inc., P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **LIGHTSTONE, Felice**; c/o Lawrence Livermore National Security, LLC, 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US). **YANG, Yue**; c/o Lawrence Livermore National Security, LLC, 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US).

(74) Agent: **BERTINO, Lauren E.** et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS



(57) Abstract: Provided herein are compounds of Formula I^a and Formula II and compositions thereof that are capable of disrupting, interrupting, and/or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Ka). The present disclosure also provides methods of treating cancers and other indications with such compounds or compositions thereof.

WO 2025/034858 A1

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*